Objective: To identify and assess artificial intelligence (AI)-enabled products reviewed by the U.S. Food and Drug Administration (FDA) that are potentially applicable to emergency medicine (EM).
Methods: The FDA AI-enabled products website was accessed to identify all marketed products as of March 2024. Board-certified EM physicians analyzed all products for applicability to EM practice. Inclusion criteria included products used by EM physicians directly or non-EM physicians participating directly in the evaluation and management of patients in an acute care setting. The Clinical and Economic Review (ICER) Evidence Rating Matrix was used to rate the net health benefit of applicable products.
Results: A total of 882 AI-enabled products have been reviewed by the FDA from 1995 to 2024. There were 272 products that were updates of prior products that were excluded, leaving 610 unique products. Products were most commonly evaluated by Radiology (454/610), Cardiovascular (59/610), and Neurology (25/610) panels. We found 154 (25 %) products applicable to EM that were approved through Radiology (121/154), Cardiovascular (24/154), Neurology (5/154), Anesthesiology (3/154), and Ophthalmology (1/154) panels. There were 30 products that were rated as having a comparable or incremental net health benefit with moderate certainty (a C+ rating).
Conclusion: An increasing number of AI-enabled products are available and regulated by the FDA. We have identified 154 that are applicable to EM, primarily related to assisting with diagnosis on various imaging modalities. There remain many opportunities for EM to assist in product reviews and meaningful translation of products into clinical practice.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajem.2024.12.062 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FDA reviewed artificial intelligence-enabled products applicable to emergency medicine.
Am J Emerg Med
December 2024
Department of Emergency Medicine, Mayo Clinic, Rochester, MN, USA.
Objective: To identify and assess artificial intelligence (AI)-enabled products reviewed by the U.S. Food and Drug Administration (FDA) that are potentially applicable to emergency medicine (EM).
View Article and Find Full Text PDFAI-enabled clinical decision support tools for mental healthcare: A product review.
Artif Intell Med
December 2024
University College London, United Kingdom of Great Britain and Northern Ireland.
Article Synopsis
- The review emphasizes the need for transparency in the availability of regulated AI-enabled Clinical Decision Support Systems (AI-CDSS) for mental healthcare, identifying seven suitable products out of 84 analyzed.
- These products are focused on diagnosing autism spectrum disorder (ASD), assessing multiple disorders through conversational analysis, and guiding medication selection using clinical and genetic data.
- It highlights that only five scientific articles evaluated the performance of these systems, with a modest overall reporting standard, showcasing the necessity for regulatory approval, strict adherence to scientific guidelines, and updated oversight measures in this rapidly evolving field.
Artificial intelligence-enabled social media listening to inform early patient-focused drug development: perspectives on approaches and strategies.
Front Digit Health
November 2024
Merck IT Centre, Merck Data & AI Organization, Merck Group, Bangalore, India.
Article Synopsis
- - The article discusses how AI-enabled social media listening (SML) can enhance patient-focused drug development (PFDD) by incorporating patient feedback from online platforms on their treatment experiences and needs.
- - It introduces a new workflow that combines human expertise and AI techniques like natural language processing (NLP) to analyze patient and caregiver posts, transforming large data sets into useful insights for drug development.
- - Two studies on patients with head and neck and esophageal cancers were conducted to test this workflow, emphasizing the importance of refining AI algorithms to ensure the accuracy and quality of the data collected, ultimately improving the rigor of SML studies in PFDD.
Embedding AI-Enabled Data Infrastructures for Sustainability in Agri-Food: Soft-Fruit and Brewery Use Case Perspectives.
Sensors (Basel)
November 2024
Interdisciplinary Institute, University of Aberdeen, Aberdeen AB24 3FX, UK.
The agri-food sector is undergoing a comprehensive transformation as it transitions towards net zero. To achieve this, fundamental changes and innovations are required, including changes in how food is produced and delivered to customers, new technologies, data and physical infrastructures, and algorithmic advancements. In this paper, we explore the opportunities and challenges of deploying AI-based data infrastructures for sustainability in the agri-food sector by focusing on two case studies: soft-fruit production and brewery operations.
View Article and Find Full Text PDFTowards a 3D-Printed Millifluidic Device for Investigating Cellular Processes.
Micromachines (Basel)
October 2024
Institute for Macromolecular Chemistry, University of Freiburg, 79104 Freiburg, Germany.
Microfluidic devices (µFDs) have been explored extensively in drug screening and studying cellular processes such as migration and metastasis. However, the fabrication and implementation of microfluidic devices pose cost and logistical challenges that limit wider-spread adoption. Despite these challenges, light-based 3D printing offers a potential alternative to device fabrication.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!